H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C. Wainwright reaffirmed its Buy rating and $50 price target on Assembly Biosciences following the company’s presentation of interim data for ABI-5366, a long-acting oral treatment for recurrent genital herpes.

H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data

Source:unsplash

Presented data showed strong antiviral activity, favorable tolerability, and a dosing profile suitable for weekly or monthly administration. The firm views these results as a key validation of Assembly’s helicase-primase inhibitor platform and believes they reduce the risk of advancing ABI-5366 into Phase 2 trials. The company plans to initiate Phase 2 clinical studies by mid-2026, signaling continued progress in its antiviral pipeline.

Assembly Biosciences, Inc. is a biotechnology company that develops and commercializes small-molecule therapies for serious viral diseases, with a particular focus on chronic hepatitis B virus (HBV) and herpesviruses.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

This article is originally published at Insider Monkey.